• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Intuitive beats The Street in Q3, increases da Vinci surgical robot base

Intuitive beats The Street in Q3, increases da Vinci surgical robot base

October 18, 2022 By Sean Whooley

Intuitive Surgical logoIntuitive Surgical (Nasdaq:ISRG) shares received a boost on third-quarter results that topped the consensus forecast.

Shares of ISRG skyrocketed after hours. They rose 11.4% to $215.85 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 3.4%.

The Sunnyvale, California-based company surgical robot maker posted profits of $324 million, or 90¢ per share, on sales of $1.56 billion for the three months ended Sept. 30, 2022, for a 5.3% bottom-line gain on sales growth of 11%.

Adjusted to exclude one-time items, earnings per share were $1.19, 7¢ ahead of Wall Street. Intuitive topped revenue projections, too, as analysts were looking for sales of $1.52 billion.

See Gary Guthart speak at DeviceTalks West Oct. 18-19

Worldwide procedures for the da Vinci surgical robot grew approximately 20% year-over-year. Intuitive noted that disruption caused by the COVID-19 pandemic impacted its procedures this time last year.

Progress for Intuitive’s Ion system

Marketing image of Intuitive's Ion robotic surgery system with Siemens Healthineers Cios Spin
The Ion system integrates with Siemens Healthineers’ Cios Spin mobile imaging system

The company also reported progress for its Ion endoluminal system. It designed Ion for robotic-assisted, minimally invasive biopsy in the lung. Ion integrates with Siemens Healthineers’ Cios Spin mobile imaging system.

On the company’s third-quarter earnings call — transcribed by AlphaStreet — CEO Gary Guthart said Ion experienced increases in installs, procedures performed and annualized system utilization.

In the quarter, Ion placements grew to 50. That marks a rise from 28 this time last year and 41 in the previous quarter. Procedures grew 211% (approximately 6,400 total), Guthart said. The system is currently under EU MDR review, and the company submitted it in China.

CFO Jamie Samath added that the company’s growth in operating expenses is attributable to the support of Ion. The company also invested further in next-generation robotics capabilities, digital capabilities and infrastructure expansion.

He said the framework allows the company to continue to invest in its new platforms, including Ion.

“Intuitive’s core business strengthened this quarter despite a challenging macroeconomic environment and some lingering pandemic impacts,” said Gary Guthart, Intuitive CEO. “Our da Vinci installed base grew to meet procedure demand, and we also see a continued increase in system utilization, which is healthy for our customers and the business.”

The company did not provide financial guidance.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, News Well, Surgical, Surgical Robotics, Wall Street Beat Tagged With: Intuitive Surgical

More recent news

  • Cooper Companies continues to see activist pressure to sell divisions, replace CEO
  • Cordis earns FDA nod for Selution SLR drug-eluting balloon
  • Siemens Healthineers links with Novo to advance liver fibrosis blood test
  • GE HealthCare rolls out AI software for predicting care bottlenecks
  • Wandercraft’s self-balancing Eve exoskeleton begins US launch

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy